---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061992"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:09:37.525314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# IN8bio Q3 net loss $7.2M; cash $12.9M; clinical progress on gamma-delta T cell trials

## Summary
- Net loss $7.2M ($0.23/sh) vs $7.4M ($0.34/sh) in Q3 2022; R&D $3.8M, G&A $3.4M.
- Cash $12.9M at Sep 30, 2023, down from $17.0M at Jun 30, 2023.
- Phase 1 INB-100 dose escalation completed; ASH data presentation Dec 11, 2023.
- Phase 2 INB-400 in newly diagnosed GBM enrollment initiated; SNO poster Nov 17.
- Phase 1 INB-200 updated data at SNO Nov 17; Cohort 3 enrollment ongoing.

## SEC filing metadata
- accession: 0000950170-23-061992
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/0000950170-23-061992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/inab-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061992
- JSON: https://secwatch.observer/filing/0000950170-23-061992.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061992.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported the three months ended September 30, 2023 results: net income Net loss of $7.2 million, or $0.23 per basic and diluted common share, EPS $0.23 per basic and diluted common share.
  - Period: the three months ended September 30, 2023
  - Net income: Net loss of $7.2 million, or $0.23 per basic and diluted common share
  - EPS: $0.23 per basic and diluted common share
  - Result: reported results
  source text: The Company reported a net loss of $7.2 million, or $0.23 per basic and diluted common share, for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017023061992/0000950170-23-061992-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.